A Randomized, Placebo-Controlled, Phase II/III Clinical Study on Inhibitory Effects of E0167 on Recurrence of Hepatocellular Carcinoma

Trial Profile

A Randomized, Placebo-Controlled, Phase II/III Clinical Study on Inhibitory Effects of E0167 on Recurrence of Hepatocellular Carcinoma

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 13 May 2011

At a glance

  • Drugs Menatetrenone (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 13 May 2011 Results published in the Hepatology.
    • 13 May 2011 Primary endpoint 'Disease-free-survival' has not been met, based on results published in Hepatology.
    • 23 Oct 2008 Planned patient number (540) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top